MyFinsight
Home
Blog
About
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$92,579K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Sales and maturities of investme...
Accrued expenses
Others
Negative Cash Flow Breakdown
Net loss
Purchase of investments
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-49,893
-43,320
-35,544
-34,978
Stock-based compensation expense
6,665
5,485
3,222
3,716
Amortization (accretion) of bond premiums/discounts
-515
-559
-3,026
-
Prepaid expenses and other current assets
-1,553
2,561
-275
6,490
Other assets
-47
-37
-
-
Accounts payable
-6,511
2,807
-8
1,869
Accrued expenses
9,140
-3,828
4,428
91
Operating lease liabilities
-67
47
-5
-6
Net cash used in operating activities
-39,581
-41,892
-30,658
-35,798
Purchase of investments
13,993
64,383
151,180
90,369
Sales and maturities of investments
60,065
67,965
79,981
39,609
Net cash used in investing activities
46,072
3,582
-71,199
-50,760
Proceeds from issuance of common stock, net of issuance costs
85,235
54,724
34,658
167,973
Proceeds from the exercise of stock options
853
149
84
49
Payment of deferred financing costs
-
-
17
-300
Net cash provided by financing activities
86,088
54,873
34,725
86,465
Net increase in cash and cash equivalents
92,579
16,563
-67,132
-93
Cash and cash equivalents at beginning of the year
62,103
45,540
112,672
74,293
Cash and cash equivalents at end of the year
154,682
62,103
45,540
112,672
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$85,235K
Proceeds from the
exercise of stock options
$853K
(131.17%↑ Y/Y)
Sales and maturities
of investments
$60,065K
(-26.85%↓ Y/Y)
Net cash provided by
financing activities
$86,088K
(5.15%↑ Y/Y)
Net cash used in
investing activities
$46,072K
(-9.18%↓ Y/Y)
Canceled cashflow
$13,993K
Net increase in cash
and cash...
$92,579K
(140.64%↑ Y/Y)
Canceled cashflow
$39,581K
Purchase of investments
$13,993K
(-55.42%↓ Y/Y)
Accrued expenses
$9,140K
(325.51%↑ Y/Y)
Stock-based compensation
expense
$6,665K
(19.40%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,553K
(-124.47%↓ Y/Y)
Other assets
-$47K
Net cash used in
operating activities
-$39,581K
(57.95%↑ Y/Y)
Canceled cashflow
$17,405K
Net loss
-$49,893K
(47.91%↑ Y/Y)
Accounts payable
-$6,511K
(-2425.36%↓ Y/Y)
Amortization (accretion) of
bond...
-$515K
Operating lease
liabilities
-$67K
(-570.00%↓ Y/Y)
Buy us a coffee